We posited in light of the critical role of IL-1β in disrupting lung endothelial barrier function during ARDS,17 a therapy targeting SARS-CoV-2 activated inflammasome–caspase-1/11–IL-1β signaling might avert lung vascular endothelial injury and edema formation and subsequent respiratory failure. This evidence concerns the gene IL1B and respiratory failure.